Supernus Pharmaceuticals (SUPN) Cash & Equivalents (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Cash & Equivalents of $180.0 million for Q2 2026, up 24.35% year-over-year from $144.7 million in Q2 2025, and down 2.66% on a QoQ basis from $184.9 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Cash & Equivalents (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Cash & Equivalents for 16 years, with the latest figure at $180.0 million in Q2 2026.
- Cash & Equivalents for Q2 2026 came in at $180.0 million, up 24.35% year-over-year; the trailing twelve-month figure through Jun 2026 was $180.0 million (up 24.35% YoY), and the FY2025 annual result was $128.4 million, up 85.27% from the prior year.
- Cash & Equivalents slipped to $180.0 million in Q2 2026, from $184.9 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $184.9 million in Q1 2026 and troughed at $24.7 million in Q2 2023.
- A 5-year average of $103.8 million and a median of $103.2 million in 2022 frame the typical range for Cash & Equivalents.
- The widest annual swing landed in 2023, when Cash & Equivalents plunged 85.75%; it then soared 377.92% in 2025.
- A 5-year view of Cash & Equivalents shows it stood at $93.1 million in 2022, then decreased by 19.4% to $75.1 million in 2023, then decreased by 7.63% to $69.3 million in 2024, then surged by 85.27% to $128.4 million in 2025, then surged by 40.1% to $180.0 million in 2026.
- Per Business Quant data, the three most recent Cash & Equivalents figures were $180.0 million in Q2 2026, $184.9 million in Q1 2026, and $128.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 164.00 Mn |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.37 Bn | 185.39 Mn | 179.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 179.95 Mn |
| Mar 31, 2026 | 184.87 Mn |
| Dec 31, 2025 | 128.45 Mn |
| Sep 30, 2025 | 151.37 Mn |
| Jun 30, 2025 | 144.71 Mn |
| Mar 31, 2025 | 115.85 Mn |
| Dec 31, 2024 | 69.33 Mn |
| Sep 30, 2024 | 31.67 Mn |
| Jun 30, 2024 | 52.09 Mn |
| Mar 31, 2024 | 63.40 Mn |
| Dec 31, 2023 | 75.05 Mn |
| Sep 30, 2023 | 94.99 Mn |
| Jun 30, 2023 | 24.71 Mn |
| Mar 31, 2023 | 58.44 Mn |
| Dec 31, 2022 | 93.12 Mn |
| Sep 30, 2022 | 111.49 Mn |
| Jun 30, 2022 | 173.43 Mn |
| Mar 31, 2022 | 115.72 Mn |
| Dec 31, 2021 | 203.43 Mn |
| Sep 30, 2021 | 215.28 Mn |